Intracellular Th Stock Buy Hold or Sell Recommendation
| ITCI Stock | USD 128.57 0.03 0.02% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Intracellular Th is 'Strong Buy'. The recommendation algorithm takes into account all of Intracellular's available fundamental, technical, and predictive indicators you will find on this site.
Check out Intracellular Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Intracellular and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Intracellular |
Execute Intracellular Buy or Sell Advice
The Intracellular recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Intracellular Th. Macroaxis does not own or have any residual interests in Intracellular Th or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Intracellular's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | Good | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Intracellular Trading Alerts and Improvement Suggestions
| Intracellular Th appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 680.85 M. Net Loss for the year was (74.68 M) with profit before overhead, payroll, taxes, and interest of 387.77 M. | |
| Intracellular Th currently holds about 628.74 M in cash with (73.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.64. | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Intra-Cellular Therapies Given Hold Rating at Needham Company LLC |
Intracellular current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Intracellular analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Intracellular analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Intracellular Returns Distribution Density
The distribution of Intracellular's historical returns is an attempt to chart the uncertainty of Intracellular's future price movements. The chart of the probability distribution of Intracellular daily returns describes the distribution of returns around its average expected value. We use Intracellular Th price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Intracellular returns is essential to provide solid investment advice for Intracellular.
| Mean Return | 0.75 | Value At Risk | -2.16 | Potential Upside | 2.51 | Standard Deviation | 4.66 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Intracellular historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Intracellular Stock Institutional Investors
| Shares | Franklin Resources Inc | 2024-12-31 | 1.8 M | Geode Capital Management, Llc | 2024-12-31 | 1.7 M | Clearbridge Advisors, Llc | 2024-12-31 | 1.7 M | Pictet Asset Manangement Sa | 2024-09-30 | 1.6 M | Suvretta Capital Management, Llc | 2024-12-31 | 1.4 M | Gw&k Investment Management, Llc | 2024-12-31 | 1.4 M | Perceptive Advisors Llc | 2024-12-31 | 1.3 M | Westfield Capital Management Company, L.p. | 2024-12-31 | 1.2 M | Holocene Advisors, Lp | 2024-12-31 | 1.2 M | Fmr Inc | 2024-12-31 | 11.1 M | Jpmorgan Chase & Co | 2024-09-30 | 10.6 M |
Intracellular Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Capital Expenditures | 266.7K | 325.7K | 778K | 269K | 322K | 376.2K | |
| Net Income | (227.0M) | (284.1M) | (256.3M) | (139.7M) | (74.7M) | (78.4M) | |
| End Period Cash Flow | 61.4M | 93.8M | 150.4M | 149.5M | 308.7M | 324.1M | |
| Change In Cash | (46.2M) | 32.3M | 56.6M | (848K) | 159.2M | 167.1M | |
| Free Cash Flow | (230.3M) | (259.9M) | (271.0M) | (124.5M) | (73.5M) | (77.2M) | |
| Depreciation | 528.1K | 533.4K | 656K | 528K | (8.5M) | (8.1M) | |
| Other Non Cash Items | 214.1K | 178.5K | 537K | (8.3M) | (54.0M) | (51.3M) | |
| Investments | (480.0M) | 280.7M | (127.6M) | 105.5M | (335.2M) | (318.4M) | |
| Change To Netincome | 21.2M | 24.6M | 30.4M | 43.1M | 49.6M | 52.0M |
Intracellular Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Intracellular or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Intracellular's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Intracellular stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.73 | |
β | Beta against Dow Jones | 0.93 | |
σ | Overall volatility | 4.95 | |
Ir | Information ratio | 0.16 |
Intracellular Volatility Alert
Intracellular Th has relatively low volatility with skewness of 6.2 and kurtosis of 42.28. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Intracellular's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Intracellular's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Intracellular Fundamentals Vs Peers
Comparing Intracellular's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Intracellular's direct or indirect competition across all of the common fundamentals between Intracellular and the related equities. This way, we can detect undervalued stocks with similar characteristics as Intracellular or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Intracellular's fundamental indicators could also be used in its relative valuation, which is a method of valuing Intracellular by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Intracellular to competition |
| Fundamentals | Intracellular | Peer Average |
| Return On Equity | -0.0858 | -0.31 |
| Return On Asset | -0.0696 | -0.14 |
| Profit Margin | (0.11) % | (1.27) % |
| Operating Margin | (0.15) % | (5.51) % |
| Current Valuation | 12.69 B | 16.62 B |
| Shares Outstanding | 106.33 M | 571.82 M |
| Shares Owned By Insiders | 3.23 % | 10.09 % |
| Shares Owned By Institutions | 96.42 % | 39.21 % |
| Number Of Shares Shorted | 1.6 M | 4.71 M |
| Price To Earning | (6.56) X | 28.72 X |
| Price To Book | 11.91 X | 9.51 X |
| Price To Sales | 20.08 X | 11.42 X |
| Revenue | 680.85 M | 9.43 B |
| Gross Profit | 387.77 M | 27.38 B |
| EBITDA | (116.72 M) | 3.9 B |
| Net Income | (74.68 M) | 570.98 M |
| Cash And Equivalents | 628.74 M | 2.7 B |
| Cash Per Share | 6.64 X | 5.01 X |
| Total Debt | 16.98 M | 5.32 B |
| Debt To Equity | 0.04 % | 48.70 % |
| Current Ratio | 9.81 X | 2.16 X |
| Book Value Per Share | 10.81 X | 1.93 K |
| Cash Flow From Operations | (73.18 M) | 971.22 M |
| Short Ratio | 0.30 X | 4.00 X |
| Earnings Per Share | (0.72) X | 3.12 X |
| Target Price | 132.0 | |
| Number Of Employees | 860 | 18.84 K |
| Beta | 0.72 | -0.15 |
| Market Capitalization | 13.67 B | 19.03 B |
| Total Asset | 1.37 B | 29.47 B |
| Retained Earnings | (1.69 B) | 9.33 B |
| Working Capital | 1.1 B | 1.48 B |
| Current Asset | 541.82 M | 9.34 B |
Note: Acquisition by Mark Neumann of 11017 shares of Intracellular subject to Rule 16b-3 [view details]
Intracellular Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Intracellular . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Intracellular Buy or Sell Advice
When is the right time to buy or sell Intracellular Th? Buying financial instruments such as Intracellular Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Intracellular in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Business Supplies Thematic Idea Now
Business Supplies
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Business Supplies theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Business Supplies Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Intracellular Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.72) | Revenue Per Share | Quarterly Revenue Growth 0.508 | Return On Assets | Return On Equity |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.